NASDAQ:CEMI - Chembio Diagnostics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$9.35 -0.15 (-1.58 %)
(As of 09/25/2018 01:33 AM ET)
Previous Close$9.50
Today's Range$9.10 - $9.45
52-Week Range$5.85 - $11.55
Volume42,300 shs
Average Volume28,603 shs
Market Capitalization$134.65 million
P/E Ratio-17.98
Dividend YieldN/A
Beta1.18
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. It offers tests for HIV and Syphilis, and Zika virus. The company also develops tests for malaria, Dengue virus, chikungunya virus, Ebola, Lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC for the development of a POC diagnostic test for traumatic brain injury; international diagnostics company to develop a POC diagnostic test for a specific type of cancer; and AstraZeneca for the development of a POC assay for a novel biomarker, as well as with LumiraDx to develop POC diagnostic tests. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

Receive CEMI News and Ratings via Email

Sign-up to receive the latest news and ratings for CEMI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CEMI
CUSIPN/A
Phone631-924-1135

Debt

Debt-to-Equity Ratio0.02
Current Ratio3.53
Quick Ratio2.58

Price-To-Earnings

Trailing P/E Ratio-17.98
Forward P/E Ratio-21.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$24.01 million
Price / Sales5.52
Cash FlowN/A
Price / CashN/A
Book Value$1.06 per share
Price / Book8.82

Profitability

EPS (Most Recent Fiscal Year)($0.52)
Net Income$-6,370,000.00
Net Margins-16.54%
Return on Equity-26.91%
Return on Assets-21.13%

Miscellaneous

Employees165
Outstanding Shares14,170,000
Market Cap$134.65 million

Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics Inc (NASDAQ:CEMI) announced its earnings results on Wednesday, August, 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.05. The business had revenue of $8.72 million for the quarter, compared to analysts' expectations of $6.94 million. Chembio Diagnostics had a negative net margin of 16.54% and a negative return on equity of 26.91%. View Chembio Diagnostics' Earnings History.

When is Chembio Diagnostics' next earnings date?

Chembio Diagnostics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Chembio Diagnostics.

What price target have analysts set for CEMI?

1 Wall Street analysts have issued 1 year price objectives for Chembio Diagnostics' shares. Their forecasts range from $14.00 to $14.00. On average, they expect Chembio Diagnostics' stock price to reach $14.00 in the next year. This suggests a possible upside of 49.7% from the stock's current price. View Analyst Price Targets for Chembio Diagnostics.

What is the consensus analysts' recommendation for Chembio Diagnostics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chembio Diagnostics.

Who are some of Chembio Diagnostics' key competitors?

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the folowing people:
  • Mr. John J. Sperzel III, Pres, CEO & Director (Age 54)
  • Mr. Neil A. Goldman, Exec. VP & CFO (Age 50)
  • Mr. Javan Esfandiari, Chief Science & Technology Officer and Exec. VP (Age 51)
  • Ms. Sharon Klugewicz, Sr. VP and Chief Quality & Regulatory Officer (Age 50)
  • Dr. Robert Passas Ph.D., Sr. VP & Chief Commercial Officer (Age 64)

Who are Chembio Diagnostics' major shareholders?

Chembio Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Acuta Capital Partners LLC (14.33%), Cortina Asset Management LLC (4.56%), Royce & Associates LP (2.11%), Gagnon Securities LLC (1.86%), Gagnon Advisors LLC (1.37%) and Benchmark Capital Advisors (0.68%). Company insiders that own Chembio Diagnostics stock include Neil A Goldman and Norman H Pessin. View Institutional Ownership Trends for Chembio Diagnostics.

Which institutional investors are buying Chembio Diagnostics stock?

CEMI stock was bought by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Royce & Associates LP, EAM Investors LLC, Gagnon Advisors LLC, Gagnon Securities LLC, Acuta Capital Partners LLC, Renaissance Technologies LLC and Benchmark Capital Advisors. Company insiders that have bought Chembio Diagnostics stock in the last two years include Neil A Goldman and Norman H Pessin. View Insider Buying and Selling for Chembio Diagnostics.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $9.35.

How big of a company is Chembio Diagnostics?

Chembio Diagnostics has a market capitalization of $134.65 million and generates $24.01 million in revenue each year. The company earns $-6,370,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Chembio Diagnostics employs 165 workers across the globe.

What is Chembio Diagnostics' official website?

The official website for Chembio Diagnostics is http://www.chembio.com.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 3661 HORSEBLOCK ROAD, MEDFORD NY, 11763. The company can be reached via phone at 631-924-1135 or via email at [email protected]


MarketBeat Community Rating for Chembio Diagnostics (NASDAQ CEMI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  98 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  201
MarketBeat's community ratings are surveys of what our community members think about Chembio Diagnostics and other stocks. Vote "Outperform" if you believe CEMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CEMI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/25/2018 by MarketBeat.com Staff

Featured Article: Technical Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel